Holen Sie sich die Stockscreener-App
1.62
14.08%
0.20
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Stra - GuruFocus
Lantern Pharma (LTRN) to Showcase AI Innovation in Rare Cancer R - GuruFocus
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026 - Yahoo Finance Singapore
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows - Foster's Daily Democrat
Fed Meeting: Whats the outlook for Lantern Pharma Incs sectorWeekly Market Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Progress Index
Why is Lantern Pharma stock soaring Monday? - MSN
LTRN stock gains 18% pre-market: FDA greenlights first pediatric cancer trial for AI-driven drug - MSN
Lantern Pharma’s Dramatic Slide Reflects Key Strategic Uncertainties - timothysykes.com
Lantern Pharma outlines $15B–$20B market potential as AI-driven pipeline advances and funding needs intensify - MSN
Lantern Pharma Inc. Announces Proposed Public Offering of Common Stock - Issuewire
Lantern Pharma Q4 2025 Earnings Call Transcript - MarketBeat
Lantern Pharma Q4 2025 slides: EPS beats as cash runway tightens - Investing.com Australia
Lantern Pharma Announces Termination of Proposed Public Offering - Issuewire
Lantern Pharma Q4 2025 slides: EPS beats as cash runway tightens By Investing.com - Investing.com South Africa
Lantern Pharma Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Lantern Pharma Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LTRN) 2026-03-30 - Seeking Alpha
Lantern Pharma (LTRN) Achieves Key Milestones in Oncology Develo - GuruFocus
Lantern Pharma Reports 2025 Results and Pipeline Progress - TipRanks
Lantern Pharma (LTRN) Dismisses False CEO Resignation Rumor - GuruFocus
Lantern Pharma Inc. announces plan for best-efforts public offering of common stock. - Bitget
Lantern Pharma (NASDAQ: LTRN) outlines AI-driven cancer pipeline and going concern risk - Stock Titan
Lantern Pharma (NASDAQ: LTRN) seeks equity via best‑efforts placement with warrants - Stock Titan
Earnings call transcript: Lantern Pharma Q4 2025 sees EPS improvement, stock jumps By Investing.com - Investing.com South Africa
Earnings call transcript: Lantern Pharma Q4 2025 sees EPS improvement, stock jumps - Investing.com Canada
Lantern Pharma (NASDAQ: LTRN) trims 2025 loss as cash runway shrinks into 2026 - Stock Titan
Q4 2025 Lantern Pharma Inc Earnings Call Transcript - GuruFocus
Lantern Pharma : Fourth Quarter 2025 Financial Results Conference Call - MarketScreener
Lantern Pharma's AI cancer platform enters beta with 25 biotech groups - Stock Titan
Dallas company secures FDA approval for pediatric cancer drug trial - The Business Journals
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report - marketscreener.com
Lantern Pharma (LTRN) price target increased by 25.00% to 25.50 - MSN
Aug Volume: What are Lantern Pharma Incs recent SEC filings showingQuarterly Performance Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
Lantern Pharma denies CEO departure claim, calls report false By Investing.com - Investing.com Australia
FDA clears Lantern Pharma trial for pediatric brain cancer drug By Investing.com - Investing.com Australia
Lantern Pharma confirms Panna Sharma continues to serve as president and CEO; alerts investors to false third-party report - MarketScreener
Lantern Pharma Stock Drops as Investors Weigh Financial Results and Clinical Pipeline - timothysykes.com
Lantern Pharma Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Why Did LTRN Stock Surge 18% In Pre-Market Today? - stocktwits.com
Lantern Pharma Drops 23.9%: Bear Market Crash Shows No Immediate Signs of Recovery - Bitget
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001 - 01net
FDA Clears Lantern Pharma and Starlight Therapeutics to Begin Phase 1 Trial of STAR-001 for Pediatric CNS Cancers - geneonline.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com
Lantern Pharma Inc. recently announced a partnership with the Poetic Alliance to launch a significant clinical trial at 14 leading cancer centers in the United States, Canada, and Israel. - Bitget
Lantern Pharma and Starlight Therapeutics announce FDA clearance of IND for a planned phase 1 pediatric CNS cancer trial of STAR-001 - marketscreener.com
0.49%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):